Nohla Therapeutics

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Nohla Therapeutics sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).

5 total trials none currently recruiting 3 completed early-phase tilt upper quartile by trial count

Nohla Therapeutics: 5 sponsored US clinical trials, none currently recruiting.

Nohla Therapeutics sponsors 5 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 3 completed. 0 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), with 2 trials.

Upper-quartile sponsor footprint

Nohla Therapeutics sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

5 total, page 1 of 1

TERMINATED Phase 2

NLA101 in Adults Receiving High Dose Chemotherapy for AML

NCT03301597
COMPLETED Phase 2

Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes

NCT01690520
TERMINATED Phase 1

Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT01701323
COMPLETED Phase 2

Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies

NCT01175785
COMPLETED Phase 1

Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia

NCT01031368

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 3

Therapeutic Areas

Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) 2
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) 2
Adult Acute Myeloid Leukemia With Del(5q) 2
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities 2
Adult Acute Myeloblastic Leukemia Without Maturation (M1) 1
Adult Acute Myeloblastic Leukemia With Maturation (M2) 1
Adult Acute Monocytic Leukemia (M5b) 1
Adult Acute Monoblastic Leukemia (M5a) 1
Adult Acute Minimally Differentiated Myeloid Leukemia (M0) 1
Adult Acute Megakaryoblastic Leukemia (M7) 1

How the Nohla Therapeutics early-phase archive is shaped

5 indexed studies, none listed as recruiting (0% open); 3 completed (60%).

Phase mix: 0 late (III/IV) vs 5 early (I/II) (early-phase heavy).

Top condition: Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) (2 trials), 9 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Nohla Therapeutics: archived-pipeline peers nationwide

Peers matched on 5 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Nohla Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%5%10%15%20%25% Total trials Recruiting share Nohla Therapeutics4YouandMeAbbott Rapid DxAccess Business GroupAcera Surgical10xBio22nd Century Group23andMe3-C Institute for Social Development
Nohla Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Nohla Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 5 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Nohla Therapeutics page

5 registered trials is a research-attention snapshot, not an endorsement of Nohla Therapeutics or any single study.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Nohla Therapeutics pipeline card: 5 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.